Document Detail


Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.
MedLine Citation:
PMID:  21495928     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Survival of childhood acute lymphoblastic leukemia (ALL) is one of the greatest medical success stories of the last four decades. Unfortunately, childhood ALL survivors experience medical late effects that increase their risk of morbidity and premature death, often due to heart and vascular disease. Research has helped elucidate the mechanisms and trajectory of direct damage to the heart from treatment exposure, particularly to anthracyclines, and has also contributed knowledge on the influences of related chronic conditions, such as obesity and insulin resistance on heart health in these survivors. This article summarizes the key issues associated with early morbidity and mortality from cardiac-related disease in childhood ALL survivors and suggests directions for interventions to improve long-term outcomes.
Authors:
Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Related Documents :
12431318 - Cardiac effects of chronic oral beta-blockade: lack of agreement between heart rate and...
17467978 - Genetic determinants of qt interval variation and sudden cardiac death.
9539858 - Dependence of temporal variability of ventricular recovery on myocardial fibrosis. role...
12848808 - Sildenafil citrate does not affect qt intervals and qt dispersion: an important observa...
21128078 - Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous...
846048 - A clinicopathological study on cardiac lesions in 64 cases of disseminated intravascula...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Expert review of hematology     Volume:  4     ISSN:  1747-4094     ISO Abbreviation:  Expert Rev Hematol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-18     Completed Date:  2011-08-10     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  101485942     Medline TA:  Expert Rev Hematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  185-97     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibiotics, Antineoplastic / adverse effects*,  therapeutic use
Child
Heart Diseases / etiology
Human Growth Hormone / deficiency,  metabolism
Humans
Metabolic Diseases / complications
Obesity / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications,  mortality,  therapy*
Stem Cell Transplantation
Grant Support
ID/Acronym/Agency:
CA021765/CA/NCI NIH HHS; P30 CA021765/CA/NCI NIH HHS; P30 CA021765-27/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 12629-01-5/Human Growth Hormone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Unfavorable-risk cytogenetics in acute myeloid leukemia.
Next Document:  Salvage therapy for relapsed chronic lymphocytic leukemia.